Magnus Momsen Net Worth

The estimated Net Worth of Magnus Momsen is at least $3.15 Million dollars as of 16 February 2021. Magnus Momsen owns over 887 units of Varian Medical Systems stock worth over $15,923 and over the last 8 years Magnus sold VAR stock worth over $3,132,868.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Magnus Momsen VAR stock SEC Form 4 insiders trading

Magnus has made over 10 trades of the Varian Medical Systems stock since 2018, according to the Form 4 filled with the SEC. Most recently Magnus exercised 887 units of VAR stock worth $14,667 on 16 February 2021.

The largest trade Magnus's ever made was selling 15,909 units of Varian Medical Systems stock on 4 December 2020 worth over $2,775,643. On average, Magnus trades about 1,702 units every 54 days since 2017. As of 16 February 2021 Magnus still owns at least 963 units of Varian Medical Systems stock.

You can see the complete history of Magnus Momsen stock trades at the bottom of the page.

What's Magnus Momsen's mailing address?

Magnus's mailing address filed with the SEC is C/O VARIAN MEDICAL SYSTEMS, INC., 3100 HANSEN WAY, MS E327, PALO ALTO, CA, 94304.

Insiders trading at Varian Medical Systems

Over the last 21 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin, and Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.

What does Varian Medical Systems do?

Complete history of Magnus Momsen stock trades at Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys